tirzepatide for obesity fda approval Zepbound (tirzepatide) injection, the first and only treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA approves Eli Lilly's Zepbound,

although this data is circumstantial, it is prudent that such patients be considered at risk rather than eligible without risk of harm

Monitor patients response to treatment closely

What People Find Helpful People experiment with a range of strategies to manage the metallic taste

How it Works GIP-1 Tirzepatide works by stimulating the GLP-1 and GIP receptors in the body, leading to increased insulin secretion, decreased glucagon secretion, and decreased appetite

The result is bigger A1C reductions and more weight loss than either drug alone

Dual receptor activation (GHRH-R + GHS-R1a) produces synergistic GH pulses that exceed either compound alone while still preserving pulsatility